Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer
Relay Therapeutics focuses on selective small-molecule inhibitors, with RLY-2608 showing promise in breast cancer and a solid cash position lasting into 2027. Financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns about expense control and sustainable cash flow. Out-licensing RLY-4008 to Elevar Therapeutics secures up to $500 million in milestones, allowing RLAY to concentrate on RLY-2608's clinical trials.
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
![]() RLY In 4 months Estimated | Other | $0.25 Per Share |
![]() RLY 1 weeks ago Paid | Other | $0.25 Per Share |
![]() RLY 6 months ago Paid | Quarterly | $0.44 Per Share |
![]() RLY 9 months ago Paid | Quarterly | $0.08 Per Share |
![]() RLY 25 Jun 2024 Paid | Quarterly | $0.35 Per Share |
![]() RLY 19 Mar 2024 Paid | Quarterly | $0.03 Per Share |
![]() RLY In 4 months Estimated | Other | $0.25 Per Share |
![]() RLY 1 weeks ago Paid | Other | $0.25 Per Share |
![]() RLY 6 months ago Paid | Quarterly | $0.44 Per Share |
![]() RLY 9 months ago Paid | Quarterly | $0.08 Per Share |
![]() RLY 25 Jun 2024 Paid | Quarterly | $0.35 Per Share |
![]() RLY 19 Mar 2024 Paid | Quarterly | $0.03 Per Share |
ARCA Exchange | US Country |
The company appears to specialize in investment management with a clear focus on diversifying its investment portfolio across various asset classes to hedge against inflation and capitalize on potential growth opportunities. The strategic allocation towards a mix of inflation-protected securities, real estate, commodities, infrastructure, and natural resources companies underlines a comprehensive approach to asset management. By investing in Exchange-Traded Products (ETPs) that provide exposure to these asset classes, the company aims to offer investors a blend of income generation, capital appreciation, and inflation protection. This strategy signifies a robust investment framework designed to navigate through varying economic environments while seeking sustainable returns.
Investments in securities issued by the United States government that are designed to protect against inflation. This typically involves Treasury Inflation-Protected Securities (TIPS), which adjust in response to inflation as measured by the Consumer Price Index, thereby offering a real rate of return guaranteed by the U.S. government.
Focusing on both domestic and international real estate securities, the company invests in stocks or ETPs related to the real estate market. This can include investments in Real Estate Investment Trusts (REITs) which provide exposure to commercial, residential, and industrial real estate sectors, offering potential income through dividends and capital appreciation.
Exposure to commodities through ETPs allows the company to invest in physical commodities like metals, energy, and agricultural products or in commodity-related companies. This diversification helps in hedging against inflation and taking advantage of growth in the commodity markets.
Investments in publicly-traded domestic and international infrastructure companies. These can include enterprises involved in the construction, management, or operation of infrastructure assets such as roads, bridges, ports, and utilities. Infrastructure investments often provide stable cash flows and have a potential inflation protection component.
Focusing on publicly-traded companies involved in the natural resources sector or commodities businesses. This can include enterprises engaged in the extraction, production, or sale of natural resources like oil, gas, metals, and minerals. Investments in this area often seek to leverage growth in the global demand for natural resources.